enVVeno (NVNO) December 2022 Investor Presentation

enVVeno Medical is developing innovative surgical and non-surgical replacement venous valves to treat chronic venous insufficiency (CVI), addressing a market of over 6 million potential U.S. patients. The company is advancing its VenoValve® device through the SAVVE U.S. pivotal trial and upcoming TAVVE first-in-human studies, with sufficient capital to fund operations through 2024.